Ibi343 bya Innovent byemereye uburyo bwo kuvura kanseri y’impyiko ya CLDN18.2 itera imbere

Ku ya 19 Kamena, Ikigo gishinzwe Isuzuma ry'Imiti (CDE) cy'Ikigo cy'Igihugu gishinzwe Ibikoresho by'Ubuvuzi (NMPA) cyatangaje ko IBI343 ya Innovent Biologics yatanzwe kugira ngo ishyirwe muri gahunda yo kuvura kanseri y’agakoko gatera kanseri ya pancreas iteye imbere cyangwa yanduye CLDN18.2 kandi imaze kuvurwa nibura inshuro ebyiri mbere.

IBI343 ni agace k’imiti kagizwe n’abantu gatuma habaho ihindagurika ry’umubiri (ADC). Iyo gafatanye n’uturemangingo twa kanseri tugaragaza CLDN18.2, gahita gashyirwa mu buryo bwa ADC buterwa na CLDN18.2, maze kagasohora umutwaro utera uburozi, bigatera kwangirika kwa ADN ndetse bigatera no kubura kwanduza uturemangingo twa kanseri.

Ku ya 9 Ukuboza 2024, amakuru aheruka yavuye mu igerageza rya Phase I (NCT05458219) rya IBI343 muri adenocarcinoma ya pancreas (PDAC) yatanzwe mu nama ngarukamwaka y’Umuryango w’Uburayi wita ku ndwara zo mu bwoko bwa European Society for Medical Oncology Asia (ESMO Asia).

Abarwayi 43 barwaye CLDN18.2-positive PDAC bavuwe na IBI343. Ibisubizo byagaragaje igipimo rusange cy’ubutabazi bw’ibanze (ORR) cya 32.6%, igipimo cy’ubutabazi bw’ibanze (cORR) cya 23.3%, n’igipimo cy’ubutabazi bw’ibanze (cDCR) cya 81.4%. Igihe cy’ubutabazi bw’ibanze (mDoR) cyari amezi 7.0, igipimo cya DoR cy’amezi 6 cya 63%, naho ubutabazi bw’ibanze budafite iterambere (PFS) bwari amezi 5.3.

Kugeza ubu, haracyari igeragezwa ryinshi ry’ikoranabuhanga rishya rirwanya kanseri mu Bushinwa rishaka abarwayi. Inama ku miti mishya n’ikoranabuhanga, ushobora kuvugana n’Ishami Mpuzamahanga ry’Ibitaro bya Oncology bya Beijing mu Karere k’Amajyepfo.

Nimero ya Terefone: 4008803716

Email：myimmnet@163.com